4 February 2010

New enzyme drug target for WT1 oncogene in treating cancer

Science|Business

Research lead

Researchers at Manchester University have discovered that the enzyme HtrA2 can rid cells of the oncogene WT1, which is believed to be responsible for a wide range of cancers. WT1 is found at high levels in many leukaemias and solid cancers such as breast and lung cancer. The researchers Jorg Hartkamp and Stefan Roberts say this will provide a new target for developing drugs to treat cancers in which WT1 expression is elevated.

While WT1 is a well-known factor in cancer, having been discovered 20 years ago, it is claimed that this study, funded by the Wellcome Trust, Cancer Research UK and the Association of International Cancer Research, is the first to identify the enzyme that can break it down.

Hartkamp said the research involved studying...

This page requires a subscription

This page is available to subscribers only. Please log in or subscribe and plug into the Science|Buisiness Network now, to get full access to all our news, events, business opportunities and subscriber-posting service.

We are the first independent news service connecting buyers and sellers of emerging technologies, across borders and across industries. We keep you ahead of the news on early-stage R&D investment – and provide opportunities for you to find and meet new investors, licensees and development partners, through our unique Science|Business Network of leading scientific institutions including the University of Cambridge, Karolinska Institute, ETH-Zürich and Imperial College London.

Be first into the next wave of technology. Click here to learn more

Note: Log in requires cookies to be enabled on your machine.

Lost your password? Enter your email address with no password and we'll send you a new password. Use this to log in, then, if you wish, click on the 'My Details' link at the top of the page to change your password.